scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1041515952 |
P356 | DOI | 10.1245/S10434-013-2976-8 |
P932 | PMC publication ID | 3853374 |
P698 | PubMed publication ID | 23702640 |
P5875 | ResearchGate publication ID | 236907613 |
P2093 | author name string | John A Chabot | |
Joseph H Graziano | |||
Binsheng Zhao | |||
Jing Qi | |||
Sharyn N Lewin | |||
Lawrence H Schwartz | |||
Saravanan Krishnamoorthy | |||
John D Allendorf | |||
Gleneara E Bates | |||
Joshua C Leinwand | |||
Robert N Taub | |||
Vesna N Slavkovic | |||
Xiaotao Guo | |||
P2860 | cites work | Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer | Q24235235 |
Malignant mesothelioma: facts, myths, and hypotheses | Q28390539 | ||
Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma | Q33386934 | ||
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. | Q33476440 | ||
Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. | Q33489828 | ||
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. | Q34543902 | ||
Intraperitoneal antineoplastic drug delivery: rationale and results | Q35121705 | ||
The transport barrier in intraperitoneal therapy | Q36030299 | ||
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer | Q36079934 | ||
Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium | Q36329816 | ||
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics | Q39668452 | ||
Intraperitoneal distribution imaging in ovarian cancer patients | Q39936525 | ||
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity | Q40847045 | ||
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity | Q42251780 | ||
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. | Q43703526 | ||
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy | Q44469531 | ||
Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. | Q46039128 | ||
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal | Q46646219 | ||
Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography | Q46770111 | ||
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | Q51301047 | ||
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study. | Q53298632 | ||
Simplified calculation of body-surface area. | Q55060911 | ||
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study | Q67520718 | ||
Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer | Q68119161 | ||
Pharmacokinetics of carboplatin after intraperitoneal administration | Q68126770 | ||
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study | Q70790917 | ||
Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route | Q71228870 | ||
Intraperitoneal cisplatin with systemic thiosulfate protection | Q71842628 | ||
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma | Q72712533 | ||
Peritoneal mesothelioma | Q74654753 | ||
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis | Q78743915 | ||
Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma | Q80980814 | ||
Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials | Q84624651 | ||
Clinical pharmacology of intraperitoneal cisplatin | Q93605817 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | chemotherapy | Q974135 |
peritoneal mesothelioma | Q7168876 | ||
P304 | page(s) | S553-9 | |
P577 | publication date | 2013-05-24 | |
P1433 | published in | Annals of Surgical Oncology | Q2853069 |
P1476 | title | Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy | |
P478 | volume | 20 Suppl 3 |
Q38261500 | Advances in malignant peritoneal mesothelioma |
Q39395657 | Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis |
Q38917015 | Preventing recurrence of diffuse malignant peritoneal mesothelioma |
Q36874468 | Quantitative 3D breast magnetic resonance imaging fibroglandular tissue analysis and correlation with qualitative assessments: a feasibility study |
Search more.